The stock of Boston Scientific Corp (NYSE:BSX) last traded at $102.43, down -0.65% from the previous session.
BSX stock price is now 1.57% away from the 50-day moving average and 9.29% away from the 200-day moving average. The market capitalization of the company currently stands at $151.54B.
With the price target maintained at $113, Needham recently Upgraded its rating from Hold to Buy for Boston Scientific Corp (NYSE: BSX). On January 10, 2025, Deutsche Bank Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $108, while ‘Needham’ rates the stock as ‘Hold’
In other news, Fitzgerald Joseph Michael, EVP & Group Pres, Cardiology sold 56,372 shares of the company’s stock on Jun 04 ’25. The stock was sold for $5,799,630 at an average price of $102.88. Upon completion of the transaction, the EVP & Group Pres, Cardiology now directly owns 178,342 shares in the company, valued at $18.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 04 ’25, Officer JOSEPH M FITZGERALD bought 56,372 shares of the business’s stock. A total of $5,799,625 was incurred on buying the stock at an average price of $102.88. A total of 0.41% of the company’s stock is owned by insiders.
During the past 12 months, Boston Scientific Corp has had a low of $71.88 and a high of $107.17. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 1.45, and a quick ratio of 0.88. According to the stock market information, the enterprise value for the company is $162755690496, which is based on a 75.05 price-to-earnings ratio, a 5.36 price-to-earnings-growth ratio, and a beta of 0.69. The fifty day moving average price for BSX is $100.8508 and a two-hundred day moving average price translates $93.7267 for the stock.
The latest earnings results from Boston Scientific Corp (NYSE: BSX) was released for 2025-03-31. The net profit margin was 11.58% and return on equity was 9.65% for BSX.
